Interleukin Genetics Inc (ILI) financial statements (2021 and earlier)

Company profile

Business Address 135 BEAVER ST
WATHAM, MA 02452
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments351181
Cash and cash equivalents351181
Receivables00000
Inventory, net of allowances, customer advances and progress billings00000
Inventory00000
Prepaid expense0111
Prepaid expense and other current assets0
Other undisclosed current assets   11
Total current assets:361292
Noncurrent Assets
Property, plant and equipment11110
Intangible assets, net (including goodwill)00000
Intangible assets, net (excluding goodwill)00000
Other noncurrent assets0000
Prepaid expense and other noncurrent assets0
Total noncurrent assets:11111
TOTAL ASSETS:4613103
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11111
Accounts payable10110
Accrued liabilities00000
Debt21   
Deferred revenue and credits33342
Total current liabilities:65452
Noncurrent Liabilities
Long-term debt and lease obligation135 14
Long-term debt, excluding current maturities135 14
Total noncurrent liabilities:135 14
Total liabilities:799517
Stockholders' equity
Stockholders' equity attributable to parent(3)(2)55(14)
Preferred stock    0
Common stock00000
Additional paid in capital13312612512094
Accumulated deficit(136)(129)(121)(115)(108)
Total stockholders' equity:(3)(2)55(14)
TOTAL LIABILITIES AND EQUITY:4613103

Income statement (P&L) ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues31222
Revenue, net11222
Cost of revenue(2)(1)(1)(2)(1)
Gross profit:10011
Operating expenses(8)(7)(7)(7)(6)
Operating loss:(7)(7)(6)(7)(5)
Nonoperating expense(1)(1)(0)(0)(0)
Investment income, nonoperating 0000
Interest and debt expense(1)(1)(0)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes11000
Loss from continuing operations before income taxes:(7)(8)(6)(7)(5)
Income tax expense    (0)
Net loss:(7)(8)(6)(7)(6)
Other undisclosed net income attributable to parent    0
Net loss available to common stockholders, diluted:(7)(8)(6)(7)(5)

Comprehensive Income ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(7)(8)(6)(7)(6)
Comprehensive loss, net of tax, attributable to parent:(7)(8)(6)(7)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: